Nanotomer, Inc
NanoTomer, Inc. is a leading targeted oncology company based in Boston, MA. Founded in 2015, their team of dedicated scientists has been at the forefront of developing innovative and cutting-edge technologies to improve patient outcomes. With a focus on addressing unmet needs in the oncology space, NanoTomer, Inc. has become a trusted provider of antibody protein drug conjugates, offering big picture insights that industry leaders depend on.
Through their proprietary antibodies, such as MHA112 and Protin101, NanoTomer, Inc. enables the targeted delivery of highly potent pharmaceuticals directly to cancerous tumors and metastatic sites. Their groundbreaking research and development efforts have the potential to revolutionize cancer therapy, autoimmune disease treatment, and CAR-T therapy. As NanoTomer, Inc. continues to achieve new milestones, they remain committed to pushing the boundaries of targeted oncology and improving the lives of patients worldwide.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.